Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.Telik, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months EndedSeptember 30,September 30,2012201120122011Operating costs and expenses:Research and development
4,464General and administrative
1,0111,5503,4235,090Total operating costs and expenses
1,8782,8556,2119,554Loss from operations
(1,878)(2,855)(6,211)(9,554)Interest and other income (expense), net
(9,523)Basic and diluted net loss per share*
(5.30)Weighted average shares used to calculate basic and diluted net loss per share*
2,3951,7992,0211,796* Adjusted for the 1-for-30 reverse stock splitSelected Balance Sheet Data(In thousands)(Unaudited)September 30,December 31,
|SOURCE Telik, Inc.|
Copyright©2012 PR Newswire.
All rights reserved